1 Thompson PD, Clarkson P, Karas RH. St atinassociatedmyopathy[J]. JAMA, 2003, 289:1681-1690.2 Tisha R. Narrative review:statin-related myopathy[J].Ann Intern Med, 2009, 150:858-868.3 Herman RJ. Drug interactions and the statins[J].CMAJ, 1999, 161:1281-1286.4 Folzenlogen D. A case of atorvastatin combinedtoxic myopathy and inflammatory myositis[J]. J ClinRheumatol, 2001, 7:340-345.5 Ertas FS, Ertas NM, Atmaca Y, et al. Unrecognized sideeffect of statin treatment:unilateral blepharoptosis[J].Ophthal Plast Reconstr Surg, 2006, 22:222-224.6 Asbach P, Paetsch I, Stawowy P, et al. Statinassociatedfocal myositis[J]. Int J Cardiol, 2009,133:e33-e34.7 Marusic S, Lisicic A, Horvatic I, et al. Atorvastatinrelatedrhabdomyolysis and acute renal failure in agenetically predisposed patient with potential drugdruginteraction[J]. Int J Clin Pharm, 2012, 34:825-827.8 Gabb GM, Vitry A, Limaye V, et al. Serious statinassociatedmyotoxicity and rhabdomyolysis inAboriginal and Torres Strait Islanders:a case series[J].Intern Med J, 2013, 43:987-992.9 Ram R, Swarnalatha G, Ramesh V, et al. Rhabdomyolysisinduced acute renal failure secondary tostatins[J]. Indian J Nephrol, 2013, 23:211-213.10 Famularo G, Gasbar rone L, Galluzzo M, et al.Atorvastatin-associated necrotising inf lammatorymyopathy[J]. Clin Exp Rheumatol, 2012, 30:981.11 Ga r cia -Es t eve z DA. Myopat hy i n a n elde rlypatient:case report[J]. Reactions, 2013, 1462:12-27.12 Rando LP, Cording SA, Newnham HH. Successfulreintroduction of statin therapy after myositis:wasthere another cause?[J]. Med J Aust, 2004, 180:472-473. 13 Ma cKay JW, Fe ne ch ME, My i nt KS. Ac ut erhabdomyolysis caused by combination therapy withatorvastatin and warfarin[J]. Br J Hosp Med(Lond),2012, 73:106-107.14 Patel AM, Shar iff S, Bailey DG, et al. Statintoxicity from macrolide antibiotic coprescription:apopulation-based cohort study[J]. Ann Intern Med,2013, 158:869-876.15 Newman CB, Palmer G, Silbershatz H, et al. Safetyof atorvastatin derived from analysis of 44 completedtrials in 9,416 patients[J]. Am J Cardiol, 2003, 92:670-676.16 Al-Omran M, Mamdani MM , Lindsay TF, et al.Suboptimal use of statin therapy in elderly patientswith atherosclerosis:A population-based study[J].Vasc Surg, 2008, 48:607-612.17 Catapano AL, Reiner Z, De Backer G, et al. ESC/EASGuidelines for the management of dyslipidaemias:TheTask Force for the management of dyslipidaemiasof the European Society of Cardiology (ESC) andthe European Atherosclerosis Society (EAS)[J].Atherosclerosis, 2011, 217:3-46.18 Amarenco P, Goldstein LB, Szarek M, et al. Effects ofintense low-density lipoprotein cholesterol reductionin patients with stroke or transient ischemic attack:TheStroke Prevention by Aggressive Reduction inCholesterol Levels (SPARCL) Trial[J]. Stroke, 2007,38:3198-3204.19 Naci H, Brugts JJ, Fleurence R, et al. Comparativeeffects of statins on major cerebrovascular events:amultiple-t reatments meta-analysis of placebocontrolledand active-comparator trials[J]. QJM, 2013,106:299-306.20 杨兴义, 陈娟娟, 李淑梅. 阿托伐他汀对高龄患者动脉粥样硬化的影响及安全性研究[J]. 中华老年医学杂志, 2012, 31:974-976.21 Mashayekhi SO, Ghandforoush-Sattari M, BaghdadchiME, et al. Patients report of statains use and sideeffctsin a sample of hospitalized cardiac patients inthe Istramic Republic of Iran[J]. East Mediterr HealthJ, 2011, 17:460-464.22 他汀类药物防治缺血性卒中/短暂性脑缺血发作专家共识组. 他汀类药物防治缺血性卒中/短暂性脑缺血发作专家共识[J]. 中国卒中杂志, 2013, 8:565-575. |